Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
|ClinicalTrials.gov Identifier: NCT00043940|
Recruitment Status : Completed
First Posted : August 16, 2002
Last Update Posted : September 16, 2011
To assess the safety of bivalirudin as an alternative anticoagulant therapy for patients with new or previous heparin-induced thrombocytopenia (HIT) / heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) undergoing percutaneous coronary intervention (PCI). This will be measured by the composite incidence of major bleeding events during administration or within 48 hours after stopping bivalirudin (or at hospital discharge, whichever occurs first). The components of the composite endpoint are: a) intracranial bleeding; b) retroperitoneal bleeding; c) bleeding that results in hemodynamic compromise; d) bleeding that requires transfusion of three or more units of whole blood or packed red cells; and e) a decrease in hemoglobin of greater than or equal to g/dL or in hematocrit of greater than or equal to 9%.
Each component of the primary composite endpoint.
To evaluate the level of anticoagulation achieved with bivalirudin. The goal is to achieve an activated clotting time (ACT) between 300 and 350 sec during PCI and 4-hour bivalirudin infusion.
To evaluate bivalirudin's effects on platelet counts.
|Condition or disease||Intervention/treatment||Phase|
|Heparin-Induced Thrombocytopenia Thrombosis||Drug: bivalirudin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Anticoagulant Therapy With Bivalirudin in the Performance of PCI in Patients With Heparin-Induced Thrombocytopenia|
|Study Start Date :||April 1999|
|Actual Primary Completion Date :||February 2003|
- Major bleeding events [ Time Frame: 48 hours ]composite incidence of major bleeding events during administration or within 48 hours after stopping bivalirudin
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00043940
|United States, North Carolina|
|Duke Clinical Research Institute, Duke University Medical Center|
|Durham, North Carolina, United States|